Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this observational study, AC5 reduced hair loss in 89% of subjects with mild androgenic alopecia, and was well tolerated and appreciated by most participants.

This study presents a new model for androgenetic alopecia progression, explaining diffuse hair loss in women through 3D reconstructions of the arrector pili muscle and its relationship with the hair follicle stem cell niche.

This study suggests that male androgenetic alopecia and female pattern hair loss follow distinct progression pathways, characterized by different trichoscopic patterns related to hair diameter and follicular unit changes.

This article reviews the genetic and androgenic factors influencing the development of androgenetic alopecia and reports no new findings; the authors highlight a need for further research into the underlying mechanisms.

This review discusses the advancements in intraoperative stem cell therapies and highlights their potential to improve hair regrowth, but it reports no new clinical results.

This study reported that using human follicle stem cells isolated from hair bulge areas increased hair density by about 29% over baseline in patients with androgenetic alopecia, with significant improvements observed 23 weeks after the last treatment.

This study found that anxiety-related traits significantly predict the impact of hair loss on quality of life across different alopecia types, with variations observed based on gender.

This study observed that androgenetic alopecia had a more significant negative impact on psychological parameters in females than males, with some differences in psychosexual outcomes based on clinical stages.

This study found that patients with a greater awareness and understanding of androgenetic alopecia were more likely to seek treatment, suggesting that education may increase treatment willingness.

Poor sleep, meat-heavy diets, and junk food worsen hair loss, while sugary drinks may help.

This review evaluates six primary studies on androgenetic alopecia treatments and suggests topical minoxidil or finasteride as first-line options, recommending further research into treatments and practice guidelines.

This study found that patients with androgenic alopecia rated their hair loss as more severe than dermatologists did, affecting their quality of life significantly.

This study found no significant immediate hair growth or loss reduction from PRP treatment compared to Finastride and placebo, but differences emerged after three to six months.

In this randomized controlled trial, daily use of a hair serum containing plant extracts and manganese PCA improved scalp tightness, reduced discomfort, and enhanced hair growth quality in men post-hair transplant, suggesting its efficacy as a dermocosmetic adjuvant for long-term hair care.

In a cross-sectional study, 46% of patients with androgenetic alopecia were found to have depression of borderline to moderate severity, while 62% reported no impact on their quality of life, emphasizing the need for awareness of psychiatric comorbidities among dermatologists.

This study found that combining minoxidil and spironolactone was more effective for hair density and severity of hair loss in women with androgenic alopecia compared to minoxidil and finasteride, with no serious adverse effects reported.

This study found that cell-free fat extract (CEFFE) enhanced hair growth in mice with androgenetic alopecia by increasing hair follicle density and promoting proliferation while regulating the DHT/AR pathway.

The researchers reported that an oral supplement containing hydrolysed fish-origin collagen, taurine, cysteine, methionine, iron, and selenium significantly improved the effectiveness of anti-hair loss treatments in people with androgenic alopecia or chronic telogen effluvium after 12 weeks, compared to drug treatments alone.

Mesenchymal stem cells could potentially help regenerate hair in people with hair loss.

This narrative review discusses the potential of urinary bladder matrix as a bio-scaffold in hair restoration but provides no new clinical results or trials; it highlights regenerative technology and suggests further exploration.

This review summarizes existing research on the use of finasteride for treating androgenetic alopecia in men, reporting its effectiveness at 1 mg/day and a strong safety profile, but presents no new findings.

This study found that US and EU experts provided similar ratings of hair loss changes from global photographs in male subjects with androgenetic alopecia, supporting the use of standardized photographic evaluations.

In this study, a shampoo and hair tonic containing the botanical extract blend Asacurin100 reduced hair loss and improved scalp health in 35 male participants with androgenetic alopecia, without serious side effects, suggesting potential efficacy that warrants larger trials for confirmation.

This article reviews potential factors contributing to hair loss in androgenetic alopecia beyond genetic predispositions and discusses current knowledge without presenting new clinical results.

This review discusses the pharmacology and safety of topical finasteride for treating androgenetic alopecia and female pattern hair loss, noting positive results but reporting no new clinical findings.

This abstract describes Upubscience Publisher as a prominent publisher of over 40 open access, peer-reviewed journals across numerous academic fields, supported by an editorial team of leading researchers. Results are not reported in this description.

This review discusses genetic factors and associated diseases linked to androgenetic alopecia but reports no new clinical findings.

This study suggests that miniaturization in pattern hair loss may occur abruptly and can be reversed with treatment, as supported by histologic evidence in finasteride-responsive patients.

This study found that using a hair serum with specific plant-derived extracts and manganese PCA improved scalp condition and hair growth in men after hair transplantation compared to controls.